Table 1.
Summary of studies investigating the use of SBRT for pulmonary oligometastases; all BED calculations are based on an assumed α/β = 10 for the metastatic tumor
| Author, year | Study design | No. patients No. with CRC | No. lung metastases No. from CRC | SBRT dose and fractionation | BED, Gy | Local control outcomes | Survival outcomes, % | Grade 3 or greater toxicity, % | Grade 2 toxicity, % |
|---|---|---|---|---|---|---|---|---|---|
| Wulf et al. [17], 2004 | retrospective | 61 (20 NSCLC) | 51 | 10–12.5 Gy × 3 | 60–94 | 80 (1 yr); | 85 (1 yr); | 0 | 3.3 |
| 4 | NR | 80 (3 yrs) | 33 (2 yrs) | ||||||
| Fritz et al. [18], 2006 | retrospective | 58 (33 NSCLC) | 31 | 30 Gy × 1 | 120 | 80 (5 yrs) | 97 (1 yr); | 0 | 0 |
| NR | NR | 73 (2 yrs); | |||||||
| 42 (5 yrs) | |||||||||
| Guckenberger et al. [19], 2007 | retrospective | 70 (38 NSCLC) | 48 | 26 Gy × 1 (n = 23); | 48–94 | 88% (2 yrs) | NR | 1.4 | 5.7 |
| NR | NR | 10–12.5 Gy × 3 (n = 19); | |||||||
| 6–7 Gy × 4–8 (n = 5) | |||||||||
| Norihisa et al. [20], 2008 | retrospective | 34 | 43 | 12–15 Gy × 4–5 | 106–132 | 90 (2 yrs) | 84 (3 yrs) | 3 | 12 |
| 9 | NR | ||||||||
| Rusthoven et al. [21], 2009 | phase I/II | 38 | 63 | 16–20 Gy × 3 | 125–180 | 100 (1 yr); | 39 (1 yr) | 7.9 | NR |
| 9 | NR | 96 (2 yrs) | |||||||
| Kim et al. [22], 2009 | retrospective | 13 | 13 | 13–17 Gy × 3 | 90–138 | 77 (1 yr); | 100 (l yr); | 0 | NR |
| 13 | 13 | 53 (2 yrs); | 76 (2 yrs) | ||||||
| 53 (3 yrs) | 65 (3 yrs) | ||||||||
| Takeda et al. [23], 2011 | retrospective | 34 | 44 | 10 Gy × 5 | 100 | 94 (1 yr; all); | NR | 3 | 6 |
| 15 | 21 | 80 (1 yr; CRC); | |||||||
| 94 (2 yrs; all); | |||||||||
| 73 (2 yrs; CRC) | |||||||||
| Qiu et al. [24], 2015 | retrospective | 65 | 144 | 5 Gy ×10 (55%); | 75–100 | NR | 43 (2 yrs) | NR | NR |
| 65 | 144 | 10 Gy × 5 (38%); other (6%) | |||||||
| Filippi et al. [25], 2015 | retrospective | 40 | 59 | 26 Gy × 1 (68%); | 94–151 | 93 (20 months) | 88 (l yr); | 0 | 7.5 |
| 40 | 59 | 15 Gy × 3 (19%); | 73 (2 yrs); | ||||||
| 11 Gy × 5 (9%); | 39 (5 yrs) | ||||||||
| 12 Gy × 4 (1%); | |||||||||
| 7.5 Gy × 8 (3%) | |||||||||
| Carvajal et al. [26], 2015 | retrospective | 13 | 13 | 34 Gy × 1 (31%); | 105–151 | 92 (1 yr) | 92 (2 yrs) | 0 | NR |
| 13 | 13 | 18 Gy × 3 (31%); | 92 (2 yrs) | ||||||
| 12.5 Gy × 4 (23%); | |||||||||
| 7.5 Gy × 8 (15%) | |||||||||
| Agolli et al. [27], 2016 | retrospective | 44 | 69 | 23–30 Gy × 1 | 76–120 | 67 (3 yrs) | 83 (1 yr); | 0 | 25 |
| 44 | 69 | 15 Gy × 3 | 68 (2 yrs); | ||||||
| 51 (3 yrs) | |||||||||
SBRT = Stereotactic body radiation therapy; BED = biological effective dose; Gy = Gray; NSCLC = non-small cell lung cancer; yr = year; yrs = years; NR = not reported; CRC = colorectal cancer.